Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500526 | 0.88 | HDAC1 (0.45) | HDAC1HDAC6CHRNA7HTR3AKCNH2 | |
| SCHEMBL6487842 | 0.88 | ACKR3 (0.42) | HDAC1HDAC6CHRNA7HTR3AFAAH | |
| SCHEMBL6495948 | 0.87 | ACKR3 (0.49) | HDAC1HDAC6FAAHACKR3NPC1 | |
| SCHEMBL6490047 | 0.87 | HDAC1 (0.44) | HDAC1HDAC6CHRNA7HTR3AACKR3 | |
| SCHEMBL6490704 | 0.87 | ACKR3 (0.41) | HDAC1HDAC6CHRNA7HTR3AFAAH | |
| SCHEMBL7119916 | 0.86 | CHRNA7 (0.61) | HDAC1HDAC6CHRNA7HTR3AKCNH2 | |
| SCHEMBL6487870 | 0.85 | CHRNA7 (0.53) | CHRNA7HTR3AKCNH2CHRNB2CHRNA4 | |
| SCHEMBL6491167 | 0.85 | USP30 (0.48) | HDAC1HDAC6CHRNA7HTR3AACKR3 | |
| SCHEMBL6501314 | 0.85 | ACKR3 (0.40) | HDAC1HDAC6CHRNA7HTR3AKCNH2 | |
| SCHEMBL6487102 | 0.84 | HDAC6 (0.46) | HDAC1HDAC6CHRNA7FAAHACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | HDAC1 467/4885HDAC6 1069/4885CHRNA7 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.